DEPTOR is an in vivo tumor suppressor that inhibits prostate tumorigenesis via the inactivation of mTORC1/2 signals

mTORC2 suppresses GSK3-dependent Snail degradation to positively regulate cancer cell invasion and metastasis

(2019) Shuo Zhang et al.   CANCER RESEARCH

Autophagy regulates apoptosis by targeting NOXA for degradation

(2018) Jingchao Wang et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Cancer statistics, 2018

(2018) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Management of Men with Prostate-specific Antigen Failure After Prostate Radiotherapy: The Case Against Early Androgen Deprivation

(2018) Douglas Brand et al.   EUROPEAN UROLOGY

Clinical and Genomic Characterization of Low–Prostate-specific Antigen, High-grade Prostate Cancer

(2018) Brandon A. Mahal et al.   EUROPEAN UROLOGY

Targeting the PI3K pathway in cancer: are we making headway?

(2018) Filip Janku et al.   Nature Reviews Clinical Oncology

The functions and regulation of the PTEN tumour suppressor: new modes and prospects

(2018) Yu-Ru Lee et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Clinical implications of PTEN loss in prostate cancer

(2018) Tamara Jamaspishvili et al.   Nature Reviews Urology

DEPTOR at the Nexus of Cancer, Metabolism, and Immunity

(2018) Alexandre Caron et al.   PHYSIOLOGICAL REVIEWS

Combined inhibition of PI3Kβ and mTOR inhibits growth of PTEN null tumours

(2018) James T Lynch et al.   MOLECULAR CANCER THERAPEUTICS

Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study

(2017) Tomasz M. Beer et al.   EUROPEAN UROLOGY

ProCAID: a phase I clinical trial to combine the AKT inhibitor AZD5363 with docetaxel and prednisolone chemotherapy for metastatic castration resistant prostate cancer

(2017) Simon J. Crabb et al.   INVESTIGATIONAL NEW DRUGS

Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition

(2017) Jane Goodall et al.   Cancer Discovery

Loss of hepatic DEPTOR alters the metabolic transition to fasting

(2017) Alexandre Caron et al.   Molecular Metabolism

Reciprocal Negative Regulation between EGFR and DEPTOR Plays an Important Role in the Progression of Lung Adenocarcinoma

(2016) X. Zhou et al.   MOLECULAR CANCER RESEARCH

DEPTOR-related mTOR suppression is involved in metformin's anti-cancer action in human liver cancer cells

(2015) Akio Obara et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate

(2015) Roberta Ferraldeschi et al.   EUROPEAN UROLOGY

Current treatment strategies for inhibiting mTOR in cancer

(2015) Francesca Chiarini et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Snail promotes cell migration through PI3K/AKT-dependent Rac1 activation as well as PI3K/AKT-independent pathways during prostate cancer progression

(2015) Veronica Henderson et al.   Cell Adhesion & Migration

Predictive Value of PTEN and AR Coexpression of Sustained Responsiveness to Hormonal Therapy in Prostate Cancer—A Pilot Study

(2015) Soha Salama El Sheikh et al.   NEOPLASIA

Targeting the mTOR-DEPTOR Pathway by CRL E3 Ubiquitin Ligases: Therapeutic Application

(2015) Yongchao Zhao et al.   NEOPLASIA

PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance

(2014) AndrewC Hsieh et al.   ASIAN JOURNAL OF ANDROLOGY

DEPTOR Expression Negatively Correlates with mTORC1 Activity and Tumor Progression in Colorectal Cancer

(2014) Er-Yong Lai et al.   Asian Pacific Journal of Cancer Prevention

Molecular mechanisms of epithelial–mesenchymal transition

(2014) Samy Lamouille et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Signaling mechanisms of the epithelial-mesenchymal transition

(2014) D. M. Gonzalez et al.   Science Signaling

Clinical significance of VEGFR-2 and 18F-FDG PET/CT SUVmax pretreatment score in predicting the long-term outcome of patients with locally advanced rectal cancer treated with neoadjuvant therapy

(2013) Claudio V. Sole et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Epithelial–Mesenchymal Transition (EMT) Induced by TNF-α Requires AKT/GSK-3β-Mediated Stabilization of Snail in Colorectal Cancer

(2013) Hao Wang et al.   PLoS One

mTOR Signaling in Growth Control and Disease

(2012) Mathieu Laplante et al.   CELL

TGF- -induced activation of mTOR complex 2 drives epithelial-mesenchymal transition and cell invasion

(2012) S. Lamouille et al.   JOURNAL OF CELL SCIENCE

Targeting Cullin-RING ligases by MLN4924 induces autophagy via modulating the HIF1-REDD1-TSC1-mTORC1-DEPTOR axis

(2012) Y Zhao et al.   Cell Death & Disease

RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome

(2011) Bo Li et al.   BMC BIOINFORMATICS

PTEN Deletion in Prostate Cancer Cells Does Not Associate with Loss of RAD51 Function: Implications for Radiotherapy and Chemotherapy

(2011) M. Fraser et al.   CLINICAL CANCER RESEARCH

Metastasis suppressors in human benign prostate, intraepithelial neoplasia, and invasive cancer: their prospects as therapeutic agents

(2011) Zahraa I. Khamis et al.   MEDICINAL RESEARCH REVIEWS

DEPTOR, an mTOR Inhibitor, Is a Physiological Substrate of SCFβTrCP E3 Ubiquitin Ligase and Regulates Survival and Autophagy

(2011) Yongchao Zhao et al.   MOLECULAR CELL

mTOR Generates an Auto-Amplification Loop by Triggering the βTrCP- and CK1α-Dependent Degradation of DEPTOR

(2011) Shanshan Duan et al.   MOLECULAR CELL

mTOR Drives Its Own Activation via SCFβTrCP-Dependent Degradation of the mTOR Inhibitor DEPTOR

(2011) Daming Gao et al.   MOLECULAR CELL

Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer

(2010) A H M Reid et al.   BRITISH JOURNAL OF CANCER

Integrative Genomic Profiling of Human Prostate Cancer

(2010) Barry S. Taylor et al.   CANCER CELL

Discovery of 1-(4-(4-Propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a Highly Potent, Selective Mammalian Target of Rapamycin (mTOR) Inhibitor for the Treatment of Cancer

(2010) Qingsong Liu et al.   JOURNAL OF MEDICINAL CHEMISTRY

mTOR: from growth signal integration to cancer, diabetes and ageing

(2010) Roberto Zoncu et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

PTEN Deficiency Is Fully Penetrant for Prostate Adenocarcinoma in C57BL/6 Mice via mTOR-Dependent Growth

(2009) Jorge Blando et al.   AMERICAN JOURNAL OF PATHOLOGY

DEPTOR Is an mTOR Inhibitor Frequently Overexpressed in Multiple Myeloma Cells and Required for Their Survival

(2009) Timothy R. Peterson et al.   CELL

An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1

(2009) Carson C. Thoreen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY